GlassScriptPhysician profile
Martin Violago
NPI 1740475482
$21,490.00
in general payments reported to CMS, 2019-2025
60 companies · $4,395 in 2025
The $4,395 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,752 · 2020: $1,686 · 2021: $2,718 · 2022: $2,725 · 2023: $3,598 · 2024: $3,614 · 2025: $4,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,607.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,242.07 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Novo Nordisk INC | $1,971.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,602.41 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $1,412.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,406.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,340.13 | 2019-2025 | |
| Amgen INC. | $914.04 | 2019-2025 | Otezla, Repatha, Evenity |
| Janssen Pharmaceuticals, INC | $850.29 | 2019-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $844.78 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Abbott Laboratories | $649.83 | 2021-2025 | Proclaim, Freestyle Libre 3, Penta |
| Otsuka America Pharmaceutical, INC. | $488.56 | 2021-2025 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $482.42 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $479.26 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $467.35 | 2019-2025 | Eliquis, Camzyos |
| Lundbeck LLC | $393.08 | 2024-2025 | Rexulti, Vyepti |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Violago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.